SCHEMBL31519

SCHEMBL31519

Cc1nc2ccc(C(=O)N3CCN(C(=O)C4CCCCC4)CC3)cn2c1-c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 1.00
FASN P49327 3/20 0.58
ACACB O00763 4/20 0.52
ACACA Q13085 4/20 0.52
KMT2A Q03164 3/20 0.49
TSHR P16473 2/20 0.49
MEN1 O00255 1/20 0.49
HPGD P15428 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
KCNK3 O14649 2/20 0.45
KCNK9 Q9NPC2 2/20 0.45
HSD11B1 P28845 2/20 0.44
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
SLC2A1 P11166 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31526 0.95 F2RL1 (0.90) F2RL1FASNACACBACACAKMT2A
SCHEMBL31533 0.91 F2RL1 (0.82) F2RL1FASNACACBACACAKMT2A
SCHEMBL15071100 0.87 F2RL1 (0.77) F2RL1KMT2ATSHRMEN1HPGD
SCHEMBL31534 0.87 F2RL1 (0.77) F2RL1FASNACACBACACAKMT2A
SCHEMBL15071146 0.86 F2RL1 (0.76) F2RL1FASNACACBACACAKMT2A
SCHEMBL15071152 0.86 F2RL1 (0.75) F2RL1FASNKMT2ATSHRMEN1
SCHEMBL15071151 0.85 F2RL1 (0.75) F2RL1FASNKMT2ATSHRMEN1
SCHEMBL31491 0.85 F2RL1 (0.75) F2RL1FASNKMT2AMEN1HPGD
SCHEMBL15071143 0.85 F2RL1 (0.74) F2RL1KMT2ATSHRMEN1HPGD
SCHEMBL15071155 0.84 F2RL1 (0.73) F2RL1FASNACACBACACAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617721-A2 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME Neopharm Co., Ltd. (KR) 2013-07-24 EP disclosed
EP-2617721-A2 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME Neopharm Co., Ltd. (KR) 2013-07-24 EP disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME NEOPHARM CO.,LTD. (KR) 2013-06-27 US disclosed
WO-2012026765-A2 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME (주)네오팜 (KR) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165652-A1 NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME F2RL1, F2R, FPR2 F2RL1 1/4885FASN 2594/4885ACACB 1316/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.